4/5
04:46 am
hcm
HUTCHMED Highlights Data to be Presented at AACR Congress 2024 [Yahoo! Finance]
Medium
Report
HUTCHMED Highlights Data to be Presented at AACR Congress 2024 [Yahoo! Finance]
4/5
04:30 am
hcm
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Medium
Report
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
4/2
01:08 am
hcm
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status [Yahoo! Finance]
Low
Report
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status [Yahoo! Finance]
4/2
01:00 am
hcm
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Low
Report
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
4/2
01:00 am
hcm
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Low
Report
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
4/2
12:36 am
hcm
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status [Yahoo! Finance]
Low
Report
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status [Yahoo! Finance]
4/2
12:30 am
hcm
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Low
Report
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
3/27
08:10 pm
hcm
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC [Yahoo! Finance]
Low
Report
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC [Yahoo! Finance]
3/27
08:00 pm
hcm
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Low
Report
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
3/27
02:06 am
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/21
08:09 pm
hcm
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China [Yahoo! Finance]
Medium
Report
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China [Yahoo! Finance]
3/21
08:00 pm
hcm
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Medium
Report
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
3/20
09:04 am
hcm
Hutchmed Is Turning Profitable [Seeking Alpha]
Low
Report
Hutchmed Is Turning Profitable [Seeking Alpha]
3/19
02:09 am
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/11
11:00 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/11
11:00 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/28
06:30 am
hcm
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
Medium
Report
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
2/6
07:04 pm
hcm
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session [Yahoo! Finance]
Low
Report
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session [Yahoo! Finance]
2/6
07:00 pm
hcm
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
Low
Report
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
2/2
09:11 am
hcm
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED [Yahoo! Finance]
Medium
Report
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED [Yahoo! Finance]
2/2
09:00 am
hcm
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
Low
Report
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
2/2
03:36 am
hcm
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership [Yahoo! Finance]
Medium
Report
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership [Yahoo! Finance]
2/2
03:30 am
hcm
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
Medium
Report
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
2/1
03:30 am
hcm
HUTCHMED to Announce 2023 Final Results
Medium
Report
HUTCHMED to Announce 2023 Final Results
1/29
11:59 pm
hcm
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer [Yahoo! Finance]